Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors

Summary

ONC-783-001 is a Phase I open label, dose-escalation study for evaluating the safety, pharmacokinetics (PK) and efficacy of ONC-783 as a single agent in patients with advanced/metastatic solid tumors, focusing on colorectal cancer, ovarian cancer, pancreatic cancer, or breast cancer.

Timeline

Start

2026-06-01

Primary completion

2027-06-01

Completion

2028-06-01

Drugs

Indications